Is NVST a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Envista Holdings (NVST) rests on Margin repair from a low base: Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. The bear case rests on dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Analysts covering it publish targets from $23.00 to $32.00 against a $24.03 share price on November 16, 2026, so even the professionals disagree by 31% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
NVST key stats
At $24.03 on November 16, 2026, Envista Holdings (NVST) has a market cap of $3.9B and a P/E of 6.2 on trailing earnings (14.4 on forward earnings). It next reports earnings around February 3, 2027 (estimated).
- Market cap
- $3.9B
- P/E (trailing)
- 6.2
- P/E (forward)
- 14.4
- EPS (trailing 12 months)
- $3.85
- Price to book
- 1.2
- Beta
- 0.94
- Next earnings
- around February 3, 2027 (estimated)
Market cap, P/E and yield are measured at the $24.03 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Envista Holdings (NVST)?
The last two weeks for Envista Holdings, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- NVST closed at $24.03 on November 16, 2026, down 7.5% over the past five trading days (from $25.97).
- Envista Holdings next reports quarterly results around February 3, 2027 (estimated).
- On November 4, 2026, Envista Holdings filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 4, 2026, Envista Holdings filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
- On November 6, 2026, UBS raised its target to $29.00 from $27.00 (Neutral).
- On November 5, 2026, Evercore ISI Group raised its target to $30.00 from $28.00 (Outperform).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Envista Holdings Corporation is a Brea, California dental products maker spun out of Danaher in 2019, selling into more than 130 countries through roughly 30 brands: Nobel Biocare and Implant Direct in implants, Ormco and Spark in orthodontics, DEXIS in imaging, and Kerr in consumables. Two reporting segments carry the business. Specialty Products & Technologies (implants, prosthetics, brackets, aligners, lab products) generated ~$1.75 billion of 2025 sales, while Equipment & Consumables (imaging systems and software, bonding agents, rotary burs, endodontic systems, infection prevention) generated ~$967 million. Around 85% of revenue comes from consumables, services and spare parts rather than capital equipment, which gives the top line a recurring shape even in quarters when dentists defer large purchases. By region, North America contributed ~$1.40 billion of 2025 sales, Western Europe ~$615 million, and emerging markets ~$586 million. The investment picture is a margin repair now several quarters old. 2024 was the trough: Envista withdrew its full-year guidance, wrote off $1.15 billion of goodwill and intangible assets, and reported a GAAP loss of $6.50 per share. Under CEO Paul Keel, who took the job that year, full-year 2025 produced 6.5% core sales growth, adjusted EBITDA of $372 million (up 26%) and adjusted EPS of $1.19. Momentum carried forward: first-half 2026 sales rose 10.5% to ~$1.44 billion with 7.1% core growth, adjusted EBITDA reached $207 million, and on August 5, 2026 management raised full-year guidance to 3.5% to 4.5% core sales growth and $1.50 to $1.55 in adjusted EPS. A wide gap persists between adjusted and GAAP results, driven mostly by intangible amortization, restructuring charges and an unusually high effective tax rate, so which figure an investor anchors on changes the valuation conclusion substantially. The stock has not followed the operating numbers in a straight line. Second-quarter 2026 revenue was ~$730.5 million, up 7.1% year over year, and adjusted EPS of $0.41 beat the ~$0.34 consensus, the fourth consecutive quarter above estimates. Even so, shares closed at $23.15 on October 16, 2026, up about 6.7% year to date and about 17% over twelve months, but down about 14% over three months from levels near $27.70 in early August. On October 15, 2026 Baird downgraded the stock to Neutral from Outperform with a $26 price target, while the broader analyst consensus (13 analysts) remains a buy with a mean target near $29.30. Third-quarter results are scheduled for November 4, 2026, with consensus adjusted EPS around $0.36 on about $689 million of revenue.
The bull case: what would have to be true for $32.00
The most optimistic published target on NVST is $32.00, +33.2% from the $24.03 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Margin repair from a low base
Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. Guidance calls for 11% to 14% adjusted EBITDA growth in 2026 against only 3.5% to 4.5% core sales growth, which implies most of the gain is coming from cost and mix rather than volume. Dental consumables peers operate at meaningfully higher margins, so how much further this can run is the part of the story still unproven.
2. Implants and aligners as the profit pool
Specialty Products & Technologies is 64% of sales and holds the franchises with the strongest pricing and clinical switching costs. Core growth there was 3.1% in the second quarter of 2026, well below the 8.5% posted by Equipment & Consumables, so the higher-margin half of the company is currently the slower-growing half. Nobel Biocare competes at the premium end against Straumann, Implant Direct plays the value tier, and Spark is the challenger to Invisalign in clear aligners.
3. Equipment demand and the imaging cycle
Equipment & Consumables lifted segment operating profit to $45.9 million on $259.5 million of second-quarter 2026 sales, a rebound after a stretch of soft dental practice capital spending. DEXIS imaging systems sit at the discretionary end of that mix and track how willing practice owners are to finance new hardware. Underneath them, restorative materials, endodontics and infection prevention products form a steadier base, part of the roughly 85% of company revenue classified as recurring.
4. Balance sheet and buybacks
Net debt stood near $310 million at the end of the second quarter of 2026 against ~$416 million of trailing adjusted EBITDA, keeping leverage under one turn. On May 5, 2026 the board authorized an additional $300 million repurchase program running through 2029, and the company bought back 2.4 million shares for ~$59 million during the quarter, following $166 million of repurchases in 2025 at an average of roughly $18.06. Envista pays no dividend, so buybacks are the entire shareholder return channel. With the share price near $23 in October 2026, below where most of the 2026 buyback ran, the remaining authorization buys more stock per dollar. One item to track on the calendar: the term loans, the revolving facility and the convertible notes all mature in August 2028, which makes 2027 a refinancing year.
The bear case: what would have to be true for $23.00
The most pessimistic published target is $23.00, -4.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Envista Holdings is worth if the risks below bite instead of the drivers above.
Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Emerging markets, about 22% of 2025 sales, carry specific pricing pressure: China's volume-based procurement program has forced steep price cuts on dental consumables and implants, and first-half 2026 emerging-market core growth was 0.8% against 8.5% in developed markets. Goodwill and other intangibles still total roughly $3.0 billion on a $5.6 billion balance sheet after the 2024 write-down, so another demand shock could produce a second impairment. Following the April 2024 guidance withdrawal, several plaintiff law firms publicised investigations of potential securities claims; Envista's fiscal 2025 Form 10-K and its second-quarter 2026 Form 10-Q name no securities class action, state that legal proceedings have not materially changed, and carry a $26.3 million accrual covering all litigation matters combined. Roughly half of revenue is earned outside the United States and a single customer accounted for 13% of second-quarter sales, so currency translation and distributor inventory swings can each move reported results independently of underlying demand. Sentiment can also turn faster than fundamentals: the shares fell about 14% in the three months to mid-October 2026 despite a second-quarter beat and raised guidance, and Baird's October 15 downgrade to Neutral is a reminder that the margin repair is now partly priced in. The November 4 third-quarter report will show whether the raised 2026 guidance holds.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding NVST already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on NVST
13 analysts cover NVST, with an average target of $28.92 (+20.3% against $24.03) and a split of 7 buy, 8 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the NVST forecast and price target page.
How is NVST valued?
Market cap, P/E and dividend yield at today's price are in the NVST key stats above. The business figures below come from Envista Holdings's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$2.86 billion; Q2 2026 up 7.1% year over year
- Margins (TTM): ~55% gross, ~10% operating, ~3% net
- Net debt: ~$310 million at the end of Q2 2026, roughly 0.7x adjusted EBITDA
As of October 2026: Two very different multiples describe the same stock: about 40x trailing GAAP earnings, and about 15x the midpoint of management's 2026 adjusted EPS guidance (analysts sit at $1.53 for 2026 and $1.66 for 2027). Bridging them are amortization of acquired intangibles, restructuring charges, and a 2025 effective tax rate near 73% created by US pre-tax losses sitting alongside $203.9 million of international pre-tax income. At roughly 1.3x trailing sales and 1.2x book value after the pullback from August levels, the market is not paying a premium on revenue or assets, the usual shape for a company whose reported earnings lag its operating improvement.
How do you decide if NVST is a buy?
Whether NVST is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NVST indirectly through an index or sector ETF before adding more.
What would change your mind on NVST
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Margin repair from a low base stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the NVST stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NVST against your real portfolio and see your actual exposure before deciding.
Your questions about Envista Holdings
Ask Walnut's AI anything about NVST and see how it fits what you own.
FAQ
Is NVST a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin repair from a low base, with revenue (ttm) at ~$2.86 billion; Q2 2026 up 7.1% year over year. The bear case rests on dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Analysts covering it are spread from $23.00 to $32.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell NVST?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $23.00, -4.3% from the $24.03 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for NVST?
+
Margin repair from a low base. Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. The most optimistic analyst target on NVST is $32.00, +33.2% from the $24.03 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for NVST?
+
Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Emerging markets, about 22% of 2025 sales, carry specific pricing pressure: China's volume-based procurement program has forced steep price cuts on dental consumables and implants, and first-half 2026 emerging-market core growth was 0.8% against 8.5% in developed markets. Goodwill and other intangibles still total roughly $3.0 billion on a $5.6 billion balance sheet after the 2024 write-down, so another demand shock could produce a second impairment. Following the April 2024 guidance withdrawal, several plaintiff law firms publicised investigations of potential securities claims; Envista's fiscal 2025 Form 10-K and its second-quarter 2026 Form 10-Q name no securities class action, state that legal proceedings have not materially changed, and carry a $26.3 million accrual covering all litigation matters combined. Roughly half of revenue is earned outside the United States and a single customer accounted for 13% of second-quarter sales, so currency translation and distributor inventory swings can each move reported results independently of underlying demand. Sentiment can also turn faster than fundamentals: the shares fell about 14% in the three months to mid-October 2026 despite a second-quarter beat and raised guidance, and Baird's October 15 downgrade to Neutral is a reminder that the margin repair is now partly priced in. The November 4 third-quarter report will show whether the raised 2026 guidance holds. The most pessimistic published target is $23.00, -4.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Envista Holdings do?
+
Envista Holdings is a dental products maker spun out of Danaher in 2019, selling implants, orthodontics and diagnostics through roughly 30 brands.
What would have to change for NVST to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin repair from a low base) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Envista Holdings actually sell?
+
Dental products, across about 30 brands sold in more than 130 countries. The lineup covers dental implants and prosthetics (Nobel Biocare, Implant Direct), orthodontic brackets and clear aligners (Ormco, Spark), digital imaging systems and software (DEXIS), and everyday clinical consumables such as bonding agents, cements, rotary burs, endodontic systems and infection prevention products (Kerr, Metrex). Roughly 85% of revenue comes from consumables, services and spare parts rather than one-off equipment sales.
How can someone invest in NVST?
+
NVST trades on the New York Stock Exchange as ordinary US common stock, so it can be bought at any US brokerage in whole or fractional shares during regular market hours. It is also held inside broad healthcare sector funds and US small- and mid-cap index funds, which provides indirect exposure without a single-stock position. Within Walnut, it can sit as one constituent of a thematic basket alongside other dental or medical device names, with a target weight set at the basket level.
Is Envista profitable?
+
Yes on both bases in the most recent periods, though the two diverge widely. Trailing twelve-month GAAP net income was about $95 million (~$0.58 diluted per share), while trailing adjusted diluted EPS was about $1.46. Full-year 2025 came in at $47 million of GAAP net income against $202 million of adjusted net income and $372 million of adjusted EBITDA. The 2024 fiscal year was a GAAP loss of $1.12 billion because of a $1.15 billion goodwill and intangible write-down. Second-quarter 2026 GAAP net income was about $53.7 million.
Walnut is informational, not investment advice, and gives no verdict on NVST. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.